Top

Published in:

01-05-2021 | Esophagus Resection | Original Article

Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma

Authors: Takeshi Morinaga, Masaaki Iwatsuki, Kohei Yamashita, Kazuto Harada, Junji Kurashige, Yohei Nagai, Shiro Iwagami, Yoshihumi Baba, Naoya Yoshida, Hideo Baba

Published in: Surgery Today | Issue 5/2021

Abstract

Purpose

In recent years, the concept of oligometastasis, which represents limited metastatic disease, has gained much interest. This study focuses on the oligometastatic recurrence (OLR) of esophageal squamous cell carcinoma (ESCC) after esophagectomy.

Methods

From among 514 patients who underwent curative resection for ESCC at our hospital between April 2005 and December 2019, 97 patients with recurrence were enrolled in this study. OLR was defined as fewer than five recurrences in a single organ. We analyzed the prognostic factors for patients with OLR after curative resection of ESCC, especially the relationship between the recurrence pattern and prognosis according to treatment, defined as metastasis-directed therapy (MDT) and chemotherapy with local therapy as combined local therapy (CLT).

Results

OLR was identified in 43 (44%) of the 97 patients with recurrence. The OLR group had a significantly better prognosis than the non-OLR group (P = 0.003). Multivariate analysis revealed that OLR was a prognostic factor after recurrence (P = 0.007) and that CLT after recurrence was the only prognostic factor in the OLR group (P = 0.024).

Conclusions

The findings of this study suggest that OLR is a prognostic factor after resection of ESCC and that CLT is a promising treatment modality for patients with OLR after curative resection of ESCC.

Available only for authorised users

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. CrossRef

Ai D, Zhu H, Ren W, Chen Y, Liu Q, Deng J, et al. Patterns of distant organ metastases in esophageal cancer: a population-based study. J Thorac Dis. 2017;9(9):3023–30. CrossRef

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. CrossRef

Toh Y, Oki E, Minami K, Okamura T. Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7(1):37–43. CrossRef

Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18(12):3353–61. CrossRef

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. CrossRef

Jamel S, Tukanova K, Markar S. Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: a systematic review. World J Gastrointest Oncol. 2019;11(9):741–9. CrossRef

Onal C, AkkusYildirim B, Guler OC. Outcomes of aggressive treatment in esophageal cancer patients with synchronous solitary brain metastasis. Mol Clin Oncol. 2017;7(1):107–12. CrossRef

Hiyoshi Y, Morita M, Kawano H, Otsu H, Ando K, Ito S, et al. Clinical significance of surgical resection for the recurrence of esophageal cancer after radical esophagectomy. Ann Surg Oncol. 2015;22(1):240–6. CrossRef

10.

Ohkura Y, Shindoh J, Ueno M, Iizuka T, Udagawa H. Clinicopathologic characteristics of oligometastases from esophageal cancer and long-term outcomes of resection. Ann Surg Oncol. 2020;27(3):651–9. CrossRef

11.

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. CrossRef

12.

Japanese Classification of Esophageal Cancer. 11th edition: part I. Esophagus. 2017a;14(1):1–36. CrossRef

13.

Japanese Classification of Esophageal Cancer. 11th Edition: part II and III. Esophagus. 2017b;14(1):37–65. CrossRef

14.

Ghaly G, Kamel M, Nasar A, Paul S, Lee PC, Port JL, et al. Locally advanced esophageal cancer: What becomes of 5-year survivors? J ThoracCardiovascSurg. 2016;151(3):726–32.

15.

Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491–524. CrossRef

16.

Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82. CrossRef

17.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16. CrossRef

18.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.s1). Eur J Cancer. 2009;45(2):228–47. CrossRef

19.

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. CrossRef

20.

Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djx015. CrossRefPubMedPubMedCentral

21.

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–65. CrossRef

22.

Baba Y, Watanabe M, Kawanaka K, Iwagami S, Ishimoto T, Iwatsuki M, et al. Radiofrequency ablation for pulmonary metastases from esophageal squamous cell carcinoma. Dis Esophagus. 2014;27(1):36–41. CrossRef

23.

Shiono S, Kawamura M, Sato T, Nakagawa K, Nakajima J, Yoshino I, et al. Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol. 2008;3(9):1046–9. CrossRef

24.

Ghaly G, Harrison S, Kamel MK, Rahouma M, Nasar A, Port JL, et al. Predictors of survival after treatment of oligometastases after esophagectomy. Ann ThoracSurg. 2018;105(2):357–62. CrossRef

25.

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74. CrossRef

26.

Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7. CrossRef

27.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. CrossRef

28.

Zhao Y, Dai Z, Min W, Sui X, Kang H, Zhang Y, et al. Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a phase III randomized trial. J Thorac Oncol. 2015;10(9):1349–56. CrossRef

29.

Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25. CrossRef

Title: Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma
Authors: Takeshi Morinaga
Masaaki Iwatsuki
Kohei Yamashita
Kazuto Harada
Junji Kurashige
Yohei Nagai
Shiro Iwagami
Yoshihumi Baba
Naoya Yoshida
Hideo Baba
Publication date: 01-05-2021
Publisher: Springer Singapore
Keywords: Esophagus Resection
Esophagus Resection
Cytostatic Therapy
Published in: Surgery Today / Issue 5/2021
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-020-02173-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2021

Surgeon fatigue does not affect surgical outcomes: a systematic review and meta-analysis

Bowel obstruction as a serious complication of patients with femoral hernia

Management options for post-esophagectomy chylothorax

Incisional hernia after liver transplantation: mesh-based repair and what else?

Inguinal hernia associated with radical prostatectomy

Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database